Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?
Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss:
- The potential impact of biosimilars at this tipping point in the pharmaceutical industry
- FDA-required suffixes and standards for biosimilars naming
- Prescription workflow best practices for small and large molecule biosimilars
- Issues raised by retrospective naming and products without suffixes
The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.
You may also like:
Everyday there are more news headlines about policymakers addressing different approaches to lowering healthcare and prescription drug costs. This spring alone saw news about the
By now, we’ve all heard: Measles is back. As of May 31, 2019, 7,981 cases of measles had been reported in the U.S in 26 states. Approximately...
At the recent NCPDP Joint Technical Work Group Meetings, held in Scottsdale in early May, the membership voted to approve three emergency external code list changes. These changes are in response to the Office of the Inspector ...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!